Several changes to NABP’s new Model Act were recommended by APC, including a requirement that licensed compounding pharmacies provide to the state board of pharmacy basic information about their compounding operations.
One hundred members of Congress signed a letter of concern sent last week to the Department of Defense in response to recent TRICARE changes that threaten beneficiaries’ access to community pharmacies, especially in rural areas.
Kentucky and Arkansas have recently proposed regulations changes to be aware of.
See inside for details, then take our survey and attend our stakeholder briefing on October 13.
The best tool you have for demonstrating the value of your therapies is your patients—what they say about the compounded medications you dispense to them.
In a Sep 16 letter to NABP CEO Al Carter, FDA states that DTE products “can put patients at harm” and that “therapies containing DTE are biological products subject to licensure under Section 351(i) of the PHS Act.”
If patient-reported outcomes can prove your value, why aren’t more of you collecting them?
One result of last week’s Compounders on Capitol Hill visits has been the creation of a joint congressional letter to FDA’s Center for Veterinary Medicine raising concerns about the great ambiguity in GFI 256 on animal compounding
Express Scripts (ESI) has slashed pharmacy reimbursements for 2023, making it impossible for many independent community pharmacies to participate in the TRICARE pharmacy network.
What if APC gave you a tool that would meet state and accreditation requirements that you have a continuous quality improvement program?
FOLLOW US
